| Title: |
Empagliflozin in Heart Failure and Previous Coronary Revascularization ; Empagliflozin in Heart Failure and Previous Coronary Revascularization: Insights From EMPEROR-Pooled |
| Authors: |
Dhingra, Nitish, K; Butler, Javed; Anker, Stefan, D; Pedro Ferreira, João; Filippatos, Gerasimos; Pfarr, Egon; Gasior, Tomasz; Nordaby, Matias; Brueckmann, Martina; Pocock, Stuart, J; Zannad, Faiez; Packer, Milton; Verma, Subodh |
| Contributors: |
St. Michael's Hospital; University of Toronto; Baylor Scott and White Research Institute Dallas, TX, USA; University of Southern Mississippi (USM); German Center for Cardiovascular Research (DZHK); Berlin Institute of Health (BIH); Berlin Institute of Health Center for Regenerative Therapies (BCRT); Charité - UniversitätsMedizin = Berlin University Medicine; Charité Campus Virchow-Klinikum (CVK); Centre d'investigation clinique plurithématique Pierre Drouin Nancy (CIC-P); Centre d'investigation clinique Nancy (CIC); Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL); Cardiovascular and Renal Clinical Trialists Vandoeuvre-les-Nancy (INI-CRCT); Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu Nancy; French-Clinical Research Infrastructure Network - F-CRIN Paris (Cardiovascular & Renal Clinical Trialists - CRCT); Défaillance Cardiovasculaire Aiguë et Chronique (DCAC); Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL); Cardiovascular Research and Development Center (UnIC@RISE); Faculdade de Medicina da Universidade do Porto (FMUP); Universidade do Porto = University of Porto; National and Kapodistrian University of Athens (NKUA); “Attikon” University Hospital; Boehringer Ingelheim International GmbH; Boehringer Ingelheim Pharma GmbH & Co. KG; University of Heidelberg, Medical Faculty; WSB University Dabrowa Górnicza; London School of Hygiene and Tropical Medicine (LSHTM); Imperial College London; Baylor Heart and Vascular Institute; This study was supported and funded by the Boehringer Ingelheim and Eli Lilly and Company Alliance |
| Source: |
ISSN: 2772-963X ; JACC. Advances ; https://hal.univ-lorraine.fr/hal-05486275 ; JACC. Advances, 2026, 5 (1), pp.102419. ⟨10.1016/j.jacadv.2025.102419⟩. |
| Publisher Information: |
CCSD; Elsevier |
| Publication Year: |
2026 |
| Collection: |
Université de Lorraine: HAL |
| Subject Terms: |
[SDV]Life Sciences [q-bio] |
| Description: |
International audience ; BACKGROUND Sodium glucose co-transporter-2 inhibitors are a foundational therapy for the management of chronic heart failure (HF). OBJECTIVES The purpose of this study was to investigate whether the efficacy of sodium glucose co-transporter-2 inhibitors in patients with HF is maintained in patients with a history of coronary revascularization. METHODS The EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure (EMPEROR)-Pooled database was a prospectively designed pooled analysis of the EMPEROR-Reduced (NCT03057977) and EMPEROR-Preserved (NCT03057951) trials, which randomized patients with HF with a left ventricular ejection fraction below and above 40%, respectively, to empagliflozin or placebo. The primary outcome was time to first HF hospitalization or cardiovascular death. We studied the baseline risk of revascularized HF patients and the impact of previous revascularization on the efficacy and safety of empagliflozin. RESULTS Overall, 3,437/9,718 (35.4%) had a history of coronary revascularization with either percutaneous coronary intervention or coronary artery bypass grafting (REVASC), and 6,281/9,718 (64.6%) did not (no REVASC). The median follow-up time was 21.23 months (IQR: 14.93-28.97 months). Of those randomized to placebo, a history of revascularization was not associated with an elevated risk of clinical outcomes, including the primary outcome and 3-point major adverse cardiac and cerebrovascular event. The efficacy and safety of empagliflozin were consistent irrespective of revascularization history for all major outcomes (primary outcome: REVASC: 0.76 [0.66-0.89], no REVASC: 0.77 [0.68-0.87], P interaction : 0.94). Empagliflozin had neutral effect on a 3-point major adverse cardiac and cerebrovascular event in both groups. CONCLUSIONS In this large HF trial program, revascularized patients with HF exhibited similar rates of HF and ischemic events as those without prior revascularization. The efficacy and safety of empagliflozin in HF were consistent in those ... |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/41609275; PUBMED: 41609275; PUBMEDCENTRAL: PMC12869890 |
| DOI: |
10.1016/j.jacadv.2025.102419 |
| Availability: |
https://hal.univ-lorraine.fr/hal-05486275; https://hal.univ-lorraine.fr/hal-05486275v1/document; https://hal.univ-lorraine.fr/hal-05486275v1/file/1-s2.0-S2772963X25008488-main.pdf; https://doi.org/10.1016/j.jacadv.2025.102419 |
| Rights: |
https://creativecommons.org/licenses/by-nc-nd/4.0/ ; https://about.hal.science/hal-authorisation-v1/ ; info:eu-repo/semantics/OpenAccess |
| Accession Number: |
edsbas.B928C23A |
| Database: |
BASE |